spring-dermatology-skin-care-2018-tracks

Page 39

Notes:

allied

academies

Journal of Dermatology Research and Skin Care | Volume 2

May 14-15, 2018 | Montreal, Canada

Spring Dermatology &

Skin Care Expo Conference

elasma is a chronic acquired hypermelanosis of the skin,

characterized by irregular brown macules symmetrically

distributedon sun-exposedareas of thebody, particularlyon the

face. It is a common cause of demand for dermatological care

that affects mainly women and more pigmented phenotypes

(Fitzpatrick skin types III-V). There are some known triggering

factors such as sun exposure, pregnancy, sexual hormones,

inflammatory processes of the skin, use of cosmetics, steroids,

and photosensitizing drugs. The main scope of therapy of

melasma is protection from sunlight and depigmentation.

Pigment reduction is achieved by using chemicals that interfere

with various steps of the melanogenesis pathways via: (i) the

retardation of proliferation of melanocytes; (ii) the inhibition

of melanosome formation and melanin synthesis; and (iii)

the enhancement of melanosome degradation. First-line

therapy usually consists of topical compounds that affect the

melanin synthesis pathway, broad-spectrum photoprotection,

and camouflage. Chemical peels are often added in second-

line therapy. Laser and light therapies represent potentially

promising options for patients who are refractory to other

modalities, but also carry a significant risk of worsening the

disease.

Speaker Biography

Renata Indelicato Zac is a Brazilian dermatologist and has her expertise in clinical and

cosmetic dermatology and is pursuing her Master’s degree in Health Science. She is

the Director of Clinica Attento, Belo Horizonte, MG, Brazil, and Mentor in dermatology

training at Minas Gerais’ Military Hospital.

Renata Indelicato Zac

Minas Gerais’ Military Hospital, Brazil

How to clinically treat melasma?